



Press release 2013-11-20

## First Order from University Hospital in Norway

**C-RAD received an order for Sentinel and Catalyst systems from a key customer in Norway. In total three units will be delivered in December to the St. Olavs University Hospital in Trondheim.**

The St. Olavs University Hospital has in total four linear accelerators in Trondheim. The Catalyst systems will be integrated in the existing linear accelerator rooms. After the installation is completed the customer will focus on using the respiratory gating functionality of Catalyst and Sentinel.

Respiratory gated treatments techniques are frequently used when the target volume is close to cardiac tissue or for special treatments in which tumor position depends on the respiratory cycle. The Catalyst and Sentinel system offer the required technology to perform such high end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery.

The Catalyst system is based on a new generation hardware and software platform for high performance optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable real-time assessment of patient positioning errors before and during treatment delivery. The system calculates isocenter adjustments and interfaces to major vendors ensure a completely integrated workflow. The C-RAD Sentinel system, based on laser technology, is offering advanced functionality for 4DCT.

Kristian Andreassen, St. Olavs University Hospital:

“We are happy to be able to offer respiratory gating to our patients. With the new Sentinel and Catalyst systems, we will be able to further increase the quality of our treatments with up-to-date treatment and verification options.”

Tim Thurn, CEO, C-RAD AB:

“I am very pleased to announce this breakthrough on the Norwegian market. Therewith customers in all Nordic countries enjoy the benefits of the C-RAD technology. Local references are important to develop the market further. We are expecting further orders in the Nordic region before the end of this year.”

### *About C-RAD*

*C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel<sup>TM</sup>, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-*



*RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. For more information on C-RAD, please visit [www.c-rad.com](http://www.c-rad.com).*

**For further information:**

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail [investors@c-rad.com](mailto:investors@c-rad.com)